stimulates the activation of B cells, which ultimately results in the production of high-affinity antibodies and the provision of long-lasting memory responses to secondary encounters with the ...

B-cell depletion with unconjugated CD20 monoclonal antibody (mAb) is used to treat rheumatoid arthritis and other autoimmune diseases. CD20-targeted immunotherapy depletes mature B cells through ...

Monash University scientists have identified an immune system power play behind serious bee venom allergy, which lands twice as many Australians in hospital emergency departments each year as snake or ...

Antibodies against B cells Rituximab is a depleting antibody directed against CD20 on the surface of B cells, which has established benefit in RA both with regards to clinical efficacy and ...

July 22, 2024 — Scientists have discovered a way to turn the body's B cells into tiny surveillance machines and antibody factories that can pump out specially designed antibodies to destroy ...

Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments ...

Ouro launched to develop antibody drugs for chronic inflammatory conditions and ... T cell engagers and therapies targeting specific subsets of malfunctioning B cells implicated in autoimmune diseases ...

A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...